JP5351889B2 - インビボおよび／またはインビトロ安定性が増大した生物学的に活性なタンパク質 - Google Patents

インビボおよび／またはインビトロ安定性が増大した生物学的に活性なタンパク質 Download PDF

Info

Publication number
JP5351889B2
JP5351889B2 JP2010512606A JP2010512606A JP5351889B2 JP 5351889 B2 JP5351889 B2 JP 5351889B2 JP 2010512606 A JP2010512606 A JP 2010512606A JP 2010512606 A JP2010512606 A JP 2010512606A JP 5351889 B2 JP5351889 B2 JP 5351889B2
Authority
JP
Japan
Prior art keywords
pas
ifna2b
amino acid
protein
biologically active
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2010512606A
Other languages
English (en)
Japanese (ja)
Other versions
JP2010531139A5 (enExample
JP2010531139A (ja
Inventor
スケラ，アメ
シーオボールド，イナ
シェラプシー，マーティン
Original Assignee
テクニシェ ユニバーシタット ミュンヘン
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39776993&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=JP5351889(B2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by テクニシェ ユニバーシタット ミュンヘン filed Critical テクニシェ ユニバーシタット ミュンヘン
Publication of JP2010531139A publication Critical patent/JP2010531139A/ja
Publication of JP2010531139A5 publication Critical patent/JP2010531139A5/ja
Application granted granted Critical
Publication of JP5351889B2 publication Critical patent/JP5351889B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/545—IL-1
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/555—Interferons [IFN]
    • C07K14/56—IFN-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/35—Fusion polypeptide containing a fusion for enhanced stability/folding during expression, e.g. fusions with chaperones or thioredoxin

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Diabetes (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Endocrinology (AREA)
  • Urology & Nephrology (AREA)
  • Cardiology (AREA)
  • Epidemiology (AREA)
  • Rheumatology (AREA)
  • Vascular Medicine (AREA)
  • Communicable Diseases (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Transplantation (AREA)
  • Oncology (AREA)
  • Pain & Pain Management (AREA)
  • Peptides Or Proteins (AREA)
JP2010512606A 2007-06-21 2008-06-20 インビボおよび／またはインビトロ安定性が増大した生物学的に活性なタンパク質 Active JP5351889B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
EP07012219 2007-06-21
EP07012219.7 2007-06-21
US7170508P 2008-05-14 2008-05-14
US61/071,705 2008-05-14
PCT/EP2008/005020 WO2008155134A1 (en) 2007-06-21 2008-06-20 Biological active proteins having increased in vivo and/or vitro stability

Publications (3)

Publication Number Publication Date
JP2010531139A JP2010531139A (ja) 2010-09-24
JP2010531139A5 JP2010531139A5 (enExample) 2012-12-06
JP5351889B2 true JP5351889B2 (ja) 2013-11-27

Family

ID=39776993

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2010512606A Active JP5351889B2 (ja) 2007-06-21 2008-06-20 インビボおよび／またはインビトロ安定性が増大した生物学的に活性なタンパク質

Country Status (19)

Country Link
US (2) US8563521B2 (enExample)
EP (2) EP2173890B1 (enExample)
JP (1) JP5351889B2 (enExample)
KR (2) KR101631323B1 (enExample)
CN (1) CN101970678B (enExample)
AT (1) ATE502114T1 (enExample)
AU (1) AU2008266448B2 (enExample)
CA (1) CA2691386C (enExample)
CY (1) CY1111491T1 (enExample)
DE (1) DE602008005596D1 (enExample)
DK (2) DK2173890T3 (enExample)
EA (1) EA021222B8 (enExample)
ES (2) ES2422007T3 (enExample)
HR (1) HRP20110368T1 (enExample)
NZ (1) NZ580670A (enExample)
PL (2) PL2173890T3 (enExample)
PT (1) PT2173890E (enExample)
SI (2) SI2369005T1 (enExample)
WO (1) WO2008155134A1 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020091068A1 (ja) * 2018-11-02 2020-05-07 味の素株式会社 融合タンパク質

Families Citing this family (217)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7846445B2 (en) 2005-09-27 2010-12-07 Amunix Operating, Inc. Methods for production of unstructured recombinant polymers and uses thereof
US7855279B2 (en) 2005-09-27 2010-12-21 Amunix Operating, Inc. Unstructured recombinant polymers and uses thereof
EP1971355B1 (en) 2005-12-20 2020-03-11 Duke University Methods and compositions for delivering active agents with enhanced pharmacological properties
US20130172274A1 (en) 2005-12-20 2013-07-04 Duke University Methods and compositions for delivering active agents with enhanced pharmacological properties
US8841255B2 (en) 2005-12-20 2014-09-23 Duke University Therapeutic agents comprising fusions of vasoactive intestinal peptide and elastic peptides
JP2010523084A (ja) 2007-03-30 2010-07-15 アンブルックス，インコーポレイテッド 修飾ｆｇｆ−２１ポリペプチド
DE602008005596D1 (de) 2007-06-21 2011-04-28 Univ Muenchen Tech Biologisch aktive proteine mit erhöhter in-vivo- und/oder in-vitro-stabilität
BRPI0815416A2 (pt) 2007-08-15 2014-10-21 Amunix Inc Composições e métodos para modificar propriedades de polipeptídeos biologicamente ativos
CA3004716C (en) 2008-04-29 2022-04-12 Ascendis Pharma Endocrinology Division A/S Pegylated recombinant human growth hormone compounds
BRPI0912683A2 (pt) 2008-05-15 2016-01-26 Transmolecular Inc tratamento de tumores metastáticos
JP2011526303A (ja) 2008-06-27 2011-10-06 デューク ユニバーシティ エラスチン様ペプチドを含む治療剤
US8703717B2 (en) 2009-02-03 2014-04-22 Amunix Operating Inc. Growth hormone polypeptides and methods of making and using same
WO2010091122A1 (en) 2009-02-03 2010-08-12 Amunix, Inc. Extended recombinant polypeptides and compositions comprising same
US8680050B2 (en) 2009-02-03 2014-03-25 Amunix Operating Inc. Growth hormone polypeptides fused to extended recombinant polypeptides and methods of making and using same
AU2010258898B8 (en) 2009-06-08 2015-02-05 Amunix Operating Inc. Glucose-regulating polypeptides and methods of making and using same
AU2010258892B2 (en) * 2009-06-08 2015-08-13 Amunix Operating Inc. Growth hormone polypeptides and methods of making and using same
US9849188B2 (en) 2009-06-08 2017-12-26 Amunix Operating Inc. Growth hormone polypeptides and methods of making and using same
BR112012004094A2 (pt) * 2009-08-24 2016-03-08 Amunix Operating Inc composições de fator vii de coagulação e métodos para fazer e usar as mesmas
SG181648A1 (en) 2009-12-15 2012-07-30 Ascendis Pharma As Dry growth hormone composition transiently linked to a polymer carrier
US8765432B2 (en) 2009-12-18 2014-07-01 Oligasis, Llc Targeted drug phosphorylcholine polymer conjugates
CN106995493B (zh) 2010-02-04 2021-09-24 卫材公司 氯毒素多肽和结合物及其应用
WO2011123830A2 (en) 2010-04-02 2011-10-06 Amunix Operating Inc. Alpha 1-antitrypsin compositions and methods of making and using same
EP4450523A3 (en) * 2010-04-02 2025-03-12 Amunix Pharmaceuticals, Inc. Binding fusion proteins, binding fusion protein-drug conjugates, xten-drug conjugates and methods of making and using same
TWI510246B (zh) 2010-04-30 2015-12-01 Molecular Partners Ag 抑制ｖｅｇｆ－ａ受體交互作用的經修飾結合性蛋白質
WO2011142858A2 (en) 2010-05-11 2011-11-17 Fred Hutchinson Cancer Research Center Chlorotoxin variants, conjugates, and methods for their use
JP6200806B2 (ja) 2010-05-21 2017-09-20 メリマック ファーマシューティカルズ インコーポレーティッド 二重特異的融合タンパク質
DK2571510T3 (en) 2010-05-21 2018-11-19 Xl Protein Gmbh BIOSYNTHETIC PROLIN / ALANIN-RANDOM COIL POLYPEPTIDES AND THEIR APPLICATIONS
RU2012157399A (ru) 2010-06-18 2014-07-27 КсайберСайенс ГмбХ Пептиды в качестве активных агентов для стабилизации биологических барьеров
DK2598526T3 (en) 2010-07-29 2018-11-19 Eleven Biotherapeutics Inc CHEMICAL IL-1 RECEPTOR TYPE-I AGONISTS AND ANTAGONISTS
US9221892B2 (en) 2010-11-26 2015-12-29 Molecular Partners Ag Capping modules for designed ankyrin repeat proteins
IL210093A0 (en) 2010-12-19 2011-06-30 David Helman Membrane bound reporter molecules and their use in cell sorting
WO2012103240A2 (en) 2011-01-25 2012-08-02 Eleven Biotherapeutics, Inc. Receptor binding agents
DK2717898T3 (en) 2011-06-10 2019-03-25 Bioverativ Therapeutics Inc COAGULATING COMPOUNDS AND PROCEDURES FOR USE THEREOF
DK3513804T3 (da) 2011-07-08 2022-06-20 Bioverativ Therapeutics Inc Kimære og hybride faktor viii-polypeptider og fremgangsmåder til anvendelse deraf
US10656167B2 (en) 2011-07-25 2020-05-19 Bioverativ Therapeutics Inc. Assays to monitor bleeding disorders
AU2012290379A1 (en) 2011-07-29 2014-02-06 Eleven Biotherapeutics, Inc. Purified proteins
IN2014CN00989A (enExample) * 2011-08-12 2015-04-10 Ascendis Pharma As
US20140323402A1 (en) * 2011-08-12 2014-10-30 Ascendis Phama A/S Protein Carrier-Linked Prodrugs
EA035323B1 (ru) 2012-01-12 2020-05-28 Биовератив Терапьютикс Инк. Полипептиды химерного фактора viii и их применение
US20130210747A1 (en) 2012-02-13 2013-08-15 University Of Southern California Methods and Therapeutics Comprising Ligand-Targeted ELPs
LT2822577T (lt) 2012-02-15 2019-03-25 Bioverativ Therapeutics Inc. Rekombinantiniai faktoriaus viii baltymai
HRP20221531T1 (hr) 2012-02-15 2023-02-17 Bioverativ Therapeutics Inc. Pripravci faktora viii i postupci dobivanja i korištenja istih
CN107496932A (zh) 2012-02-27 2017-12-22 阿穆尼克斯运营公司 Xten缀合组合物和制造其的方法
US10568934B2 (en) 2012-05-07 2020-02-25 Allergan, Inc. Method of treating AMD in patients refractory to anti-VEGF therapy
AU2013270683A1 (en) 2012-06-08 2014-12-11 Biogen Ma Inc. Chimeric clotting factors
CA2875246A1 (en) 2012-06-08 2013-12-12 Biogen Idec Ma Inc. Procoagulant compounds
RU2014150224A (ru) 2012-06-28 2016-08-20 Молекьюлар Партнерс Аг Сконструированный белок с анкириновым повтором, связывающийся с фактором роста тромбоцитов
WO2014008480A2 (en) 2012-07-06 2014-01-09 Biogen Idec Ma Inc. Cell line expressing single chain factor viii polypeptides and uses thereof
US10138291B2 (en) 2012-07-11 2018-11-27 Bioverativ Therapeutics Inc. Factor VIII complex with XTEN and von Willebrand Factor protein, and uses thereof
US20150218280A1 (en) 2012-08-10 2015-08-06 University Of Southern California CD20 scFv-ELPs METHODS AND THERAPEUTICS
US20140092376A1 (en) * 2012-10-01 2014-04-03 Momentive Performance Materials, Inc. Container and method for in-line analysis of protein compositions
CA2888806A1 (en) 2012-10-18 2014-04-24 Biogen Idec Ma Inc. Methods of using a fixed dose of a clotting factor
HK1214539A1 (zh) 2012-10-30 2016-07-29 Bioverativ Therapeutics Inc. 應用viii因子多肽的方法
US20150290328A1 (en) 2012-11-20 2015-10-15 Phasebio Pharmaceuticals, Inc. Formulations of active agents for sustained release
EP2738180A1 (en) 2012-11-30 2014-06-04 Molecular Partners AG Binding proteins comprising at least two binding domains against HER2.
US20140179560A1 (en) 2012-12-10 2014-06-26 Fred Hutchinson Cancer Research Center Drug discovery methods and platforms
TWI674270B (zh) 2012-12-11 2019-10-11 英商梅迪繆思有限公司 用於治療肥胖之升糖素與glp-1共促效劑
LT2956477T (lt) 2013-02-15 2021-02-10 Bioverativ Therapeutics Inc. Optimizuotas faktoriaus viii genas
CA2903706C (en) 2013-03-13 2024-01-23 Eleven Biotherapeutics, Inc. Chimeric cytokine formulations for ocular delivery
HK1220383A1 (zh) 2013-03-14 2017-05-05 Medimmune Limited 用於治疗肥胖症的聚乙二醇化的胰高血糖素和glp-1共激动剂
PL3666283T3 (pl) 2013-03-15 2022-10-03 Bioverativ Therapeutics Inc. Formulacje polipeptydu czynnika viii
EA037906B1 (ru) 2013-03-15 2021-06-04 Биовератив Терапьютикс Инк. Препараты полипептида фактора ix
WO2014210558A1 (en) 2013-06-28 2014-12-31 Biogen Idec Ma Inc. Thrombin cleavable linker with xten and its uses thereof
WO2015022326A1 (en) 2013-08-12 2015-02-19 Xiber Science Gmbh Peptides as active agents for treating primary graft dysfunction
EP3033097B1 (en) 2013-08-14 2021-03-10 Bioverativ Therapeutics Inc. Factor viii-xten fusions and uses thereof
US20160311885A1 (en) 2013-08-14 2016-10-27 Biogen Ma Inc. Recombinant factor viii proteins
JP6463361B2 (ja) 2013-09-08 2019-01-30 コディアック サイエンシーズ インコーポレイテッドＫｏｄｉａｋ Ｓｃｉｅｎｃｅｓ Ｉｎｃ． 第ｖｉｉｉ因子両性イオンポリマーコンジュゲート
US11559580B1 (en) 2013-09-17 2023-01-24 Blaze Bioscience, Inc. Tissue-homing peptide conjugates and methods of use thereof
HUE057005T2 (hu) 2013-09-25 2022-04-28 Bioverativ Therapeutics Inc Oszlopon történõ vírusinaktiváló eljárások
CA2927012A1 (en) 2013-11-05 2015-05-14 Allergan, Inc. Method of treating conditions of the eye with an anti-vegf darpin
WO2015070014A1 (en) 2013-11-08 2015-05-14 Biogen Idec Ma Inc. Procoagulant fusion compound
US20160296600A1 (en) 2013-11-11 2016-10-13 Ascendis Pharma Relaxin Division A/S Relaxin Prodrugs
DE102013113156A1 (de) 2013-11-28 2015-05-28 Freie Universität Berlin Verbindung und Verfahren zur selektiven Radiomarkierung von Polypeptiden mittels Festphasensynthese
EP3082848B1 (en) 2013-12-06 2023-10-18 Bioverativ Therapeutics Inc. Population pharmacokinetics tools and uses thereof
WO2015095553A1 (en) 2013-12-20 2015-06-25 Nephrogenesis, Llc Methods and apparatus for kidney dialysis
DK3091997T5 (da) 2014-01-10 2024-10-14 Bioverativ Therapeutics Inc Kimære faktor viii-proteiner og anvendelser deraf
EP3113792B1 (en) 2014-03-05 2018-12-05 Merz Pharma GmbH & Co. KGaA Novel recombinant clostridial neurotoxins with increased duration of effect
SG10201913735SA (en) 2014-03-24 2020-03-30 Bioverativ Therapeutics Inc Lyophilized factor ix formulations
EP2937096B1 (en) 2014-04-23 2019-08-21 Julius-Maximilians-Universität Würzburg Peptides derived from RS1 which down-regulate glucose absorption after a glucose rich meal and increase insulin sensitivity
US9840553B2 (en) 2014-06-28 2017-12-12 Kodiak Sciences Inc. Dual PDGF/VEGF antagonists
EP3160478A4 (en) 2014-06-30 2018-05-16 Bioverativ Therapeutics Inc. Optimized factor ix gene
US9616114B1 (en) 2014-09-18 2017-04-11 David Gordon Bermudes Modified bacteria having improved pharmacokinetics and tumor colonization enhancing antitumor activity
SG11201701803XA (en) 2014-09-26 2017-04-27 Bayer Pharma AG Stabilized adrenomedullin derivatives and use thereof
PT3186192T (pt) 2014-09-30 2018-04-09 Thena Biotech S R L Uma proteína de fusão, uma nanopartícula composta por uma pluralidade de monómeros da dita proteína de fusão e utilizações das mesmas
EP3207130B1 (en) 2014-10-14 2019-08-07 Halozyme, Inc. Compositions of adenosine deaminase-2 (ada2), variants thereof and methods of using same
JP6849590B2 (ja) 2014-10-17 2021-03-24 コディアック サイエンシーズ インコーポレイテッドＫｏｄｉａｋ Ｓｃｉｅｎｃｅｓ Ｉｎｃ． ブチリルコリンエステラーゼ両性イオン性ポリマーコンジュゲート
MA40835A (fr) 2014-10-23 2017-08-29 Biogen Ma Inc Anticorps anti-gpiib/iiia et leurs utilisations
CN107108710B (zh) 2014-10-24 2022-02-15 百时美施贵宝公司 修饰的fgf-21多肽及其用途
MA40861A (fr) 2014-10-31 2017-09-05 Biogen Ma Inc Anticorps anti-glycoprotéines iib/iiia
KR20250059541A (ko) 2014-11-18 2025-05-02 아센디스 파마 엔도크리놀로지 디비전 에이/에스 신규한 중합체성 hGH 프로드러그
PT3220892T (pt) 2014-11-21 2021-11-05 Ascendis Pharma Endocrinology Div A/S Formas de dosagem de hormona do crescimento de longa ação
JP7075757B2 (ja) 2014-11-21 2022-05-26 フェーズバイオ ファーマシューティカルズ，インコーポレイテッド 制御放出および持続的放出のためのｅｌｐ融合タンパク質
WO2016094627A1 (en) 2014-12-10 2016-06-16 S-Aima Holding Company, Llc Generation of hemoglobin-based oxygen carriers using elastin-like polypeptides
WO2016130518A2 (en) 2015-02-09 2016-08-18 Phasebio Pharmaceuticals, Inc. Methods and compositions for treating muscle disease and disorders
WO2016145237A1 (en) * 2015-03-11 2016-09-15 Yu Fu-Shin X Composition and methods to promote wound healing
RU2769470C2 (ru) 2015-04-02 2022-04-01 Молекьюлар Партнерс Аг Рекомбинантные связывающие белки и их применение
US10676723B2 (en) 2015-05-11 2020-06-09 David Gordon Bermudes Chimeric protein toxins for expression by therapeutic bacteria
TWI726889B (zh) 2015-06-10 2021-05-11 英商梅迪繆思有限公司 蛋白酶抗性之脂化肽
TW201718627A (zh) * 2015-06-11 2017-06-01 梅茲製藥有限兩合公司 重組梭菌神經毒素及其使用與形成方法、包括其之醫藥組合物及對應其之前驅物、編碼前驅物之核酸序列及其獲得方法與前驅物之形成方法、載體與包括核酸序列之重組宿主細胞
MX2018001497A (es) 2015-08-03 2018-05-15 Bioverativ Therapeutics Inc Proteinas de fusion de factor ix y metodos para producirlas y usarlas.
IL319047A (en) 2015-08-28 2025-04-01 Amunix Operating Inc Chimeric polypeptide composition and methods for its preparation and use
US10040840B2 (en) 2015-10-02 2018-08-07 Silver Creek Pharmaceuticals, Inc. Bi-specific annexin A5/IGF-1 proteins and methods of use thereof to promote regeneration and survival of tissue
WO2017083491A2 (en) * 2015-11-10 2017-05-18 Proteothera, Inc. Methods of producing and purifying matrix-binding fusion proteins by ion-exchange chromatography
KR102654180B1 (ko) 2015-12-22 2024-04-04 엑스엘-프로테인 게엠베하 프롤린 및 알라닌 잔기가 풍부한 반복적인 아미노산 서열을 암호화하고 낮은 반복적인 뉴클레오티드 서열을 갖는 핵산
WO2017117464A1 (en) 2015-12-30 2017-07-06 Kodiak Sciences Inc. Antibodies and conjugates thereof
MX2018008050A (es) 2016-01-08 2018-08-23 Ascendis Pharma Growth Disorders As Agonistas de peptido natriuretico tipo c (cnp) de liberacion controlada con estabilidad endopeptidasa neutral (nep) incrementada.
LT3400019T (lt) 2016-01-08 2022-12-12 Ascendis Pharma Growth Disorders A/S Cnp provaistai su prie žiedo fragmento prijungtu nešikliu
WO2017118693A1 (en) 2016-01-08 2017-07-13 Ascendis Pharma Growth Disorders A/S Cnp prodrugs with large carrier moieties
CA3008017C (en) 2016-01-08 2024-01-02 Ascendis Pharma Growth Disorders A/S Controlled-release cnp agonists with reduced side-effects
BR112018011008A2 (en) 2016-01-08 2018-12-04 Ascendis Pharma Growth Disorders A/S low npr-c binding controlled release cnp agonists
EP3400022A1 (en) 2016-01-08 2018-11-14 Ascendis Pharma Growth Disorders A/S Controlled-release cnp agonists with low initial npr-b activity
EP3405480B1 (en) 2016-01-20 2022-08-03 Merz Pharma GmbH & Co. KGaA Novel recombinant clostridial neurotoxins with increased duration of effect
PL3411478T3 (pl) 2016-02-01 2022-10-03 Bioverativ Therapeutics Inc. Geny zoptymalizowanego czynnika VIII
BR112018017091A2 (pt) 2016-03-01 2019-01-02 Ascendis Pharma Bone Diseases As profármacos de pth
ES2893838T3 (es) 2016-03-02 2022-02-10 Merz Pharma Gmbh & Co Kgaa Composición que comprende toxina botulínica
EA201891946A1 (ru) 2016-03-10 2019-04-30 Медиммун Лимитед Коагонисты глюкагона и glp-1 для лечения ожирения
US12048732B2 (en) 2016-04-15 2024-07-30 Blaze Bioscience, Inc. Methods of treating breast cancer
JP2019526526A (ja) * 2016-05-04 2019-09-19 ナフィゴ プロテインズ ゲゼルシャフト ミット ベシュレンクテル ハフツングＮａｖｉｇｏ Ｐｒｏｔｅｉｎｓ ＧｍｂＨ ペプチドリンカーを含む化学的部分の部位特異的カップリングのための標的化合物
KR102449167B1 (ko) 2016-05-06 2022-09-28 파세비오 파마수티컬스 인코포레이티드 제어된 지속 방출을 위한 elp 융합 단백질
EP3484523A1 (en) 2016-07-13 2019-05-22 Ascendis Pharma A/S Conjugation method for carrier-linked prodrugs
CN109789189B (zh) 2016-09-29 2024-01-23 阿森迪斯药物骨疾病股份有限公司 控释pth化合物的剂量方案
HUE062117T2 (hu) 2016-09-29 2023-09-28 Ascendis Pharma Growth Disorders As Kombinációs terápia szabályozott felszabadulású CNP agonistákkal
ES3012647T3 (en) 2016-09-29 2025-04-09 Ascendis Pharma Bone Diseases As Controlled-release pth compounds
NZ751745A (en) 2016-09-29 2023-05-26 Ascendis Pharma Bone Diseases As Pth compounds with low peak-to-trough ratios
WO2018102743A1 (en) 2016-12-02 2018-06-07 Bioverativ Therapeutics Inc. Methods of treating hemophilic arthropathy using chimeric clotting factors
BR112019011198A2 (pt) 2016-12-02 2019-12-17 Bioverativ Therapeutics Inc métodos de indução de tolerância imune a fatores de coagulação
US11129906B1 (en) 2016-12-07 2021-09-28 David Gordon Bermudes Chimeric protein toxins for expression by therapeutic bacteria
US11180535B1 (en) 2016-12-07 2021-11-23 David Gordon Bermudes Saccharide binding, tumor penetration, and cytotoxic antitumor chimeric peptides from therapeutic bacteria
MA47163A (fr) 2016-12-16 2019-11-06 Biogen Ma Inc Facteur 11 de différenciation de croissance activé protéolytiquement stabilisé
EA201991768A1 (ru) 2017-01-31 2020-01-22 Байоверетив Терапьютикс Инк. Слитые белки на основе фактора ix и способы их получения и пути применения
LT3596116T (lt) 2017-03-16 2023-11-10 Alpine Immune Sciences, Inc. Imunomoduliacinių baltymų pd-l1 variantai ir jų naudojimo būdai
CN110809581A (zh) 2017-03-16 2020-02-18 高山免疫科学股份有限公司 Pd-l2变体免疫调节蛋白及其用途
CA3054068A1 (en) 2017-03-16 2018-09-20 Alpine Immune Sciences, Inc. Cd80 variant immunomodulatory proteins and uses thereof
AU2018250695A1 (en) 2017-04-14 2019-11-07 Kodiak Sciences Inc. Complement factor D antagonist antibodies and conjugates thereof
DK3612208T5 (da) 2017-04-21 2024-09-02 Volution Immuno Pharmaceuticals Sa Coversin til behandlingen af autoimmune sygdomme med blisterdannelse
EP3642222A1 (en) 2017-06-20 2020-04-29 Merz Pharma GmbH & Co. KGaA Novel recombinant botulinum toxin with increased duration of effect
WO2018234455A1 (en) 2017-06-21 2018-12-27 Xl-Protein Gmbh Conjugates of protein drugs and p/a peptides
US10174302B1 (en) 2017-06-21 2019-01-08 Xl-Protein Gmbh Modified L-asparaginase
FI3642340T3 (fi) 2017-06-21 2024-06-18 Jazz Pharmaceuticals Ireland Ltd Muunneltu l-asparaginaasi
EP3649143B1 (en) 2017-07-06 2022-08-31 Merz Pharma GmbH & Co. KGaA Novel recombinant botulinum neurotoxins with increased duration of effect
JP7374883B2 (ja) 2017-08-09 2023-11-07 バイオベラティブ セラピューティクス インコーポレイテッド 核酸分子およびその使用
MX2020004540A (es) 2017-10-18 2020-08-03 Alpine Immune Sciences Inc Proteinas inmunomoduladoras de ligando icos variante y composiciones y metodos relacionados.
ES2923152T3 (es) 2017-11-06 2022-09-23 Thena Biotech S R L Proteínas de fusión basadas en ferritina humana y péptidos escindibles por proteasas y su uso como vehículos quimioterapéuticos
EP3483619A1 (en) * 2017-11-13 2019-05-15 Technische Universität München Automated noninvasive determining the sex of an embryo of and the fertility of a bird's egg
WO2019126576A1 (en) 2017-12-21 2019-06-27 Amunix Pharmaceuticals, Inc. Release segments and binding compositions comprising same
EP3735417A1 (en) 2018-01-03 2020-11-11 Alpine Immune Sciences, Inc. Multi-domain immunomodulatory proteins and methods of use thereof
WO2019152692A1 (en) 2018-02-01 2019-08-08 Bioverativ Therapeutics, Inc. Use of lentiviral vectors expressing factor viii
BR112020017872A2 (pt) 2018-03-02 2020-12-22 Kodiak Sciences Inc. Anticorpos de il-6 e construtos de fusão e conjugados dos mesmos
GB201804092D0 (en) * 2018-03-14 2018-04-25 Imperial Innovations Ltd Methods and compositions
WO2019185706A1 (en) 2018-03-28 2019-10-03 Ascendis Pharma A/S Conjugates
MA52662A (fr) 2018-03-28 2021-02-17 Ascendis Pharma Oncology Div A/S Conjugués d'il-2
US11359000B2 (en) 2018-03-28 2022-06-14 Bristol-Myers Squibb Company Interleukin-2/Interleukin-2 receptor alpha fusion proteins and methods of use
RS66972B1 (sr) 2018-05-18 2025-07-31 Bioverativ Therapeutics Inc Metode lečenja hemofilije a
HRP20250963T1 (hr) 2018-05-18 2025-10-10 Ascendis Pharma Bone Diseases A/S Početna doza pth konjugata
WO2019241758A1 (en) 2018-06-15 2019-12-19 Alpine Immune Sciences, Inc. Pd-1 variant immunomodulatory proteins and uses thereof
KR20210027426A (ko) 2018-07-03 2021-03-10 브리스톨-마이어스 스큅 컴퍼니 Fgf21 제제
CN119955796A (zh) 2018-08-09 2025-05-09 比奥维拉迪维治疗股份有限公司 核酸分子及其用于非病毒基因疗法的用途
IL280880B2 (en) 2018-08-27 2025-04-01 Regeneron Pharma Using Raman Spectroscopy in Downstream Purification
US20220047673A1 (en) 2018-09-10 2022-02-17 Volution Immuno Pharmaceuticals Sa Coversin for Use in the Treatment of Rheumatic Diseases
KR20250154552A (ko) 2018-09-27 2025-10-28 실리오 디벨럽먼트, 인크. 마스킹된 사이토카인 폴리펩타이드
CN111040021B (zh) * 2018-10-12 2023-06-02 浙江道尔生物科技有限公司 一种改善生物活性蛋白性质的载体蛋白
CN111153965A (zh) 2018-11-07 2020-05-15 浙江道尔生物科技有限公司 用于改善活性蛋白或多肽性能的人工重组蛋白及其应用
JP2022513626A (ja) 2018-11-26 2022-02-09 ノバルティス アーゲー Ｌｐｌ－ｇｐｉｈｂｐ１融合ポリペプチド
CN113727998A (zh) 2018-11-30 2021-11-30 高山免疫科学股份有限公司 Cd86变体免疫调节蛋白及其用途
BR112021010047A2 (pt) 2018-12-06 2021-08-24 Bioverativ Therapeutics Inc. Uso de vetores lentivirais expressando o fator ix
KR102891411B1 (ko) 2019-02-11 2025-11-25 아센디스 파마 본 디지즈 에이/에스 Pth 접합체의 액체 약학 제제
WO2020165081A1 (en) 2019-02-11 2020-08-20 Ascendis Pharma Growth Disorders A/S Dry pharmaceutical formulations of cnp conjugates
JP7524206B2 (ja) 2019-03-04 2024-07-29 アセンディス ファーマ エンドクライノロジー ディヴィジョン エー／エス １日ごとのソマトロピンよりも優れた効力を有する長時間作用性成長ホルモン剤形
EP3956456A1 (en) 2019-04-17 2022-02-23 Codiak BioSciences, Inc. Compositions of exosomes and aav
GB201905810D0 (en) * 2019-04-25 2019-06-05 Volution Immuno Pharmaceuticals Sa Method of treatment
MX2021014649A (es) 2019-06-04 2022-01-06 Molecular Partners Ag Dominio de repetición de anquirina diseñado con estabilidad mejorada.
EP3986918A1 (en) 2019-06-18 2022-04-27 Bayer Aktiengesellschaft Adrenomedullin-analogues for long-term stabilization and their use
CN114026080A (zh) 2019-06-21 2022-02-08 阿森迪斯药物股份有限公司 含有提供π-电子对的杂芳族氮的化合物的缀合物
AU2020296297B2 (en) 2019-06-21 2025-06-12 Ascendis Pharma A/S Conjugates of heteroaromatic nitrogen-comprising compounds
AU2020296295B2 (en) 2019-06-21 2025-05-29 Ascendis Pharma A/S Conjugates of an electron-donating nitrogen or tertiary amine comprising compounds
CN115551530A (zh) 2019-08-27 2022-12-30 通尼克斯制药有限公司 经修饰的tff2多肽
WO2021062374A1 (en) 2019-09-27 2021-04-01 Duke University Tabletization of peptide self-assemblies and methods of making and using the same
US20220370556A1 (en) 2019-09-27 2022-11-24 Volution Immuno Pharmaceuticals Sa Method of Treatment
CN115279896A (zh) 2019-09-30 2022-11-01 比奥维拉迪维治疗股份有限公司 慢病毒载体配制品
WO2021072265A1 (en) 2019-10-10 2021-04-15 Kodiak Sciences Inc. Methods of treating an eye disorder
CN116925237A (zh) 2019-12-31 2023-10-24 北京质肽生物医药科技有限公司 Glp-1和gdf15的融合蛋白以及其缀合物
AU2020419444A1 (en) 2020-01-03 2022-06-09 Ascendis Pharma A/S Conjugates undergoing intramolecular rearrangements
WO2021139744A1 (en) 2020-01-11 2021-07-15 Beijing Ql Biopharmaceutical Co., Ltd. Conjugates of fusion proteins of glp-1 and fgf21
US20230042670A1 (en) 2020-01-13 2023-02-09 Ascendis Pharma Bone Diseases A/S Hypoparathyroidism Treatment
CN115812077A (zh) 2020-05-08 2023-03-17 高山免疫科学股份有限公司 April和baff抑制性免疫调节蛋白及其使用方法
IL298642A (en) 2020-06-03 2023-01-01 Ascendis Pharma Oncology Div A/S il-2 sequences and uses thereof
MX2023000156A (es) 2020-06-24 2023-02-16 Bioverativ Therapeutics Inc Metodos para la eliminacion de factor viii libre de preparaciones de vectores lentivirales modificados para expresar dicha proteina.
EP4188410B1 (en) 2020-07-30 2025-11-05 Silver Creek Pharmaceuticals, Inc. Chimeric proteins for use in the treatment of central nervous system disorders
EP4192508A1 (en) 2020-08-05 2023-06-14 Ascendis Pharma A/S Conjugates comprising reversible linkers and uses thereof
WO2022032187A1 (en) 2020-08-07 2022-02-10 Bristol-Myers Squibb Company Fgf21 combined with ccr2/5 antagonists for the treatment of fibrosis
JP2023540701A (ja) 2020-08-28 2023-09-26 アセンディス ファーマ オンコロジー ディヴィジョン エー／エス グリコシル化ｉｌ－２タンパク質及びその使用
TW202228784A (zh) 2020-09-23 2022-08-01 奧地利商艾柏力維亞生技有限公司 用以於一患者中螯合非預期的抗ｐｅｇ抗體的化合物
EP4217004A1 (en) 2020-09-28 2023-08-02 Ascendis Pharma Bone Diseases A/S Improvement of physical and mental well-being of patients with hypoparathyroidism
JP2023545684A (ja) 2020-09-30 2023-10-31 ベイジン キューエル バイオファーマシューティカル カンパニー，リミテッド ポリペプチドコンジュゲートおよび使用の方法
US20240123031A1 (en) 2020-11-25 2024-04-18 Bristol-Myers Squibb Company Methods of treating liver diseases
US20240018265A1 (en) 2020-12-11 2024-01-18 Friedrich Miescher Institute For Biomedical Research Hdac6 binding proteins and their anti-viral use
CA3200238A1 (en) 2020-12-22 2022-06-30 Jonas SCHILZ Antibodies specific for structurally disordered sequences
BR112023018802A2 (pt) 2021-04-01 2023-10-31 Ascendis Pharma As Uso de hormônio de crescimento de ação prolongada para o tratamento de doenças induzidas por inflamação
EP4323399A4 (en) 2021-04-14 2025-04-09 Kodiak Sciences Inc. Methods of treating an eye disorder
CA3218973A1 (en) * 2021-05-14 2022-11-17 Antlia Bioscience, Inc. Modified b-type natriuretic peptide
TW202313974A (zh) 2021-06-08 2023-04-01 瑞典商阿斯特捷利康公司 用於治療肝病之組合療法
AU2022334711A1 (en) 2021-08-23 2024-04-04 Bioverativ Therapeutics Inc. Baculovirus expression system
WO2023046732A1 (en) 2021-09-22 2023-03-30 Ascendis Pharma Bone Diseases A/S Long-acting pth compound treatments
WO2023110758A1 (en) 2021-12-13 2023-06-22 Ascendis Pharma Growth Disorders A/S Effective doses of cnp conjugates
CA3252113A1 (en) 2022-03-30 2023-10-05 Beijing Ql Biopharmaceutical Co Ltd Liquid pharmaceutical compositions of polypeptide conjugates and their methods of use
CN119789847A (zh) 2022-05-23 2025-04-08 阿森迪斯药物生长障碍股份有限公司 Cnp化合物的液体药物制剂
EP4342460A1 (en) 2022-09-21 2024-03-27 NovoArc GmbH Lipid nanoparticle with nucleic acid cargo
WO2024094673A1 (en) 2022-11-02 2024-05-10 Ascendis Pharma Bone Diseases A/S Pth treatment regimen comprising two pth compounds
WO2024104922A1 (en) 2022-11-14 2024-05-23 Ascendis Pharma Growth Disorders A/S Method of improving skeletal muscle function
GB202218084D0 (en) 2022-12-01 2023-01-18 Volution Immuno Pharmaceuticals Sa Fusion proteins
WO2024194300A1 (en) 2023-03-20 2024-09-26 Ascendis Pharma Growth Disorders A/S Method of treatment of a thoracolumbar deformity in a human subject with achondroplasia
WO2025030053A1 (en) 2023-08-01 2025-02-06 Insmed Incorporated Novel igg proteases and methods of use thereof
WO2025046121A1 (en) 2023-09-01 2025-03-06 Novoarc Gmbh Lipid nanoparticle with nucleic acid cargo and ionizable lipid
WO2025051711A1 (en) 2023-09-04 2025-03-13 Ascendis Pharma Bone Diseases A/S Pth treatment of chronic kidney disease
WO2025088193A1 (en) 2023-10-27 2025-05-01 Xl-Protein Gmbh Methods for efficient recombinant production of polypeptides
WO2025088192A1 (en) 2023-10-27 2025-05-01 Xl-Protein Gmbh Methods for the coupling of di(alkyl)amines to polypeptides
WO2025233381A1 (en) 2024-05-07 2025-11-13 Technische Universität München, in Vertretung des Freistaates Bayern Enzymes that eliminate pyrimidine and/or purine nucleosides for treating cancer

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FI92601C (fi) * 1992-03-11 1994-12-12 Marja Makarow Menetelmä hyötyproteiinien erittämiseksi hiivoista
US20030190740A1 (en) * 1998-10-13 2003-10-09 The University Of Georgia Research Foundation, Inc Stabilized bioactive peptides and methods of identification, synthesis, and use
WO2002002597A2 (en) 2000-06-30 2002-01-10 Maxygen Aps Peptide extended glycosylated polypeptides
JP5735194B2 (ja) 2005-01-25 2015-06-17 セル セラピューティクス インコーポレーテッド 改善された生体内半減期を有する生物学的に活性なタンパク質
JP4897792B2 (ja) * 2005-04-20 2012-03-14 ビロメッド カンパニー， リミテッド 融合タンパク質の分離のための組成物および方法
US7855279B2 (en) 2005-09-27 2010-12-21 Amunix Operating, Inc. Unstructured recombinant polymers and uses thereof
EP1996937A4 (en) 2006-03-06 2009-04-08 Amunix Inc GENETIC PACKS AND USES THEREOF
DE602008005596D1 (de) 2007-06-21 2011-04-28 Univ Muenchen Tech Biologisch aktive proteine mit erhöhter in-vivo- und/oder in-vitro-stabilität
WO2010091122A1 (en) 2009-02-03 2010-08-12 Amunix, Inc. Extended recombinant polypeptides and compositions comprising same

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020091068A1 (ja) * 2018-11-02 2020-05-07 味の素株式会社 融合タンパク質

Also Published As

Publication number Publication date
SI2173890T1 (sl) 2011-06-30
DK2173890T3 (da) 2011-06-27
US20100292130A1 (en) 2010-11-18
EP2369005A1 (en) 2011-09-28
ES2362386T3 (es) 2011-07-04
EA021222B1 (ru) 2015-05-29
CA2691386A1 (en) 2008-12-24
AU2008266448B2 (en) 2013-06-13
ATE502114T1 (de) 2011-04-15
PL2173890T3 (pl) 2011-07-29
CN101970678B (zh) 2014-08-20
US8563521B2 (en) 2013-10-22
SI2369005T1 (sl) 2013-09-30
WO2008155134A1 (en) 2008-12-24
US20140050693A1 (en) 2014-02-20
KR101631323B1 (ko) 2016-06-17
CN101970678A (zh) 2011-02-09
KR20150092355A (ko) 2015-08-12
EP2369005B1 (en) 2013-04-03
AU2008266448A1 (en) 2008-12-24
EP2173890B1 (en) 2011-03-16
KR20100044732A (ko) 2010-04-30
KR101701080B1 (ko) 2017-01-31
DE602008005596D1 (de) 2011-04-28
EA021222B8 (ru) 2015-11-30
ES2422007T3 (es) 2013-09-06
CA2691386C (en) 2014-12-23
HK1156980A1 (en) 2012-06-22
DK2369005T3 (da) 2013-06-24
EP2173890A1 (en) 2010-04-14
CY1111491T1 (el) 2015-08-05
HRP20110368T1 (hr) 2011-06-30
PL2369005T3 (pl) 2013-10-31
EA201000040A1 (ru) 2010-06-30
NZ580670A (en) 2011-09-30
PT2173890E (pt) 2011-05-06
US9260494B2 (en) 2016-02-16
JP2010531139A (ja) 2010-09-24

Similar Documents

Publication Publication Date Title
JP5351889B2 (ja) インビボおよび／またはインビトロ安定性が増大した生物学的に活性なタンパク質
JP5828889B2 (ja) プロリン／アラニンランダムコイルポリペプチドの生合成およびその使用
AU2017273743B2 (en) Serum albumin-binding fibronectin type III domains
JP7703541B2 (ja) 血清アルブミン結合性フィブロネクチンｉｉｉ型ドメインおよびその使用
AU2013203326B2 (en) Biological active proteins having increased in vivo and/or in vitro stability
HK1156980B (en) Biological active proteins having increased in vivo and/or vitro stability
HK40006593A (en) Serum albumin-binding fibronectin type iii domains
HK40006036B (en) Serum albumin-binding fibronectin type iii domains
HK40006036A (en) Serum albumin-binding fibronectin type iii domains

Legal Events

Date Code Title Description
A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20110609

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20121016

A871 Explanation of circumstances concerning accelerated examination

Free format text: JAPANESE INTERMEDIATE CODE: A871

Effective date: 20121016

A975 Report on accelerated examination

Free format text: JAPANESE INTERMEDIATE CODE: A971005

Effective date: 20121024

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20121113

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20130213

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20130220

RD03 Notification of appointment of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7423

Effective date: 20130425

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20130513

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20130502

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20130515

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20130813

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20130823

R150 Certificate of patent or registration of utility model

Ref document number: 5351889

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250